Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Evotec AG ( (EVO) ) has provided an announcement.
On November 5, 2025, Evotec SE announced its financial results for the first nine months of 2025, highlighting a strategic shift in its revenue mix aimed at long-term growth. The company reported a decrease in group revenues by 7.1% to €535.1 million, primarily due to a 12.3% decline in the Discovery & Preclinical Development segment. However, Just – Evotec Biologics outperformed expectations with an 11.3% increase in revenues. Significant agreements were signed with Sandoz and Bristol Myers Squibb, potentially bringing substantial future revenues and royalties. Despite current challenges, Evotec confirmed its 2025 guidance and 2028 outlook, emphasizing strategic collaborations and cost reduction initiatives.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
Evotec AG’s overall stock score is primarily impacted by its financial performance challenges, particularly in profitability and cash generation. Technical analysis shows mixed signals, while valuation metrics are unfavorable due to negative earnings. The earnings call provides some optimism with strategic initiatives, but overall caution is advised due to underlying financial weaknesses.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a German biotechnology company focused on drug discovery and development solutions. The company operates primarily in the discovery and preclinical development segment, as well as biologics manufacturing through its Just – Evotec Biologics division. Evotec collaborates with pharmaceutical and biotechnology companies to advance drug candidates and has a market focus on innovative therapeutic solutions.
Average Trading Volume: 48,006
Technical Sentiment Signal: Sell
Current Market Cap: $1.45B
Find detailed analytics on EVO stock on TipRanks’ Stock Analysis page.